Gene Section
Mini Review

PRKAR1A (protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1))

Constantine A Stratakis, Ludmila Matyakhina

Unit on Genetics & Endocrinology (UGEN), Developmental Endocrinology Branch (DEB), NICHD, NIH, Building 10, Room 10N262, 10 Center Drive, MSC 1862, Bethesda, MD 20892-1862, USA (CAS, LM)

Published in Atlas Database: October 2004
Online updated version: http://AtlasGeneticsOncology.org/Genes/PRKAR1AID387.html
DOI: 10.4267/2042/38131

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2004 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: R1A; CAR; CNC1; MGC17251; PKR1; PRKAR1; TSE1
HGNC (Hugo): PRKAR1A
Location: 17q23-24

DNA/RNA

Description
The RI alpha gene is composed of 10 coding exons of varying lengths, separated by introns, giving the gene a total length of at least 21 kb.

Transcription
By alternative splicing, the PRKAR1A gene encodes 3 types of transcripts that all translate in the same protein.

Protein

Description
48 kDa; contains two tandem cAMP-binding domains at the C-terminus and the dimerization domain at the N-terminus that serves also as a docking site for A Kinase Anchoring Proteins (AKAPs).

Expression
Ubiquitously expressed, in particular in brain, endocrine tissues, adipose tissue and bone.

Localisation
Predominantly cytoplasmic; nuclear traslocation possible.

Function
Two regulatory subunits bind to two catalytic...
PKA activation occurs when 2 cAMP molecules bind to each regulatory subunit, eliciting a reversible conformational change that releases the now active catalytic subunits. Subunits forming an heterotetramer, the inactive holoenzyme protein kinase A (PKA) or cyclic AMP-dependent protein kinase. Four different regulatory subunits and three catalytic subunits of PKA have been identified in humans. The protein encoded by PRKAR1A is just one of the four possible regulatory subunits of the PKA tetramer; however, PRKAR1A is the most abundant and widely expressed PKA subunit. Although its other functions are not fully elucidated yet, PRKAR1A may act as a tumor-suppressor gene in Carney complex (CNC) and in sporadic (non-CNC-related) adrenal and thyroid tumors.

**Homology**

Prkar1a, Mus musculus.
Gene conserved in Mammalia: M.musculus-81.36%; R.norvegicus-97.38%; C.elegans-57.91%; D.melanogaster-72.07%; S. cerevisiae-37.41%.

**Mutations**

**Germinal**
Most mutations are null alleles; they are dispersed throughout the coding region of the gene.

**Somatic**
Many of tumors that develop in patients with Carney complex and PPNAD (see below) show loss of heterozygosity; somatic mutations in the PRKARIA gene have been reported in three cases of sporadic adrenocortical tumors.

**Implicated in**

**Carney complex syndrome, type I**

**Disease**
A multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, psammomatous melanotic schwannomas and some other tumors.

**Prognosis**
According to the severity of the disease in a given patient, and to the quality of a regular follow up; life span is decreased in patients with CNC. 57% of the deaths are due to heart related causes; others due to the postoperative complications or evolution of the malignant process; presymptomatic diagnosis improves survival data and might prevent earlier the main causes of death in this disease.

**Cytogenetics**
Limited data; some of myxomas and PPNAD from CNC patients showed telomeric associations, dicentric chromosomes, aneuploidy, polyploidy and chromosomal rearrangements.

**Hybrid/Mutated gene**
Half of CNC patients show PRKARIA mutations.

**Oncogenesis**
PRKARIA is frequently affected by bi-allelic inactivation in tumors of CNC patients. However 1 kindred was described where a splice site mutation led to exon 6 skipping and an expressed shorter PRKAR1A protein. The mutant protein was present in patients' leukocytes and tumors, and in vitro studies indicated that the mutant PRKAR1A activated cAMP-dependent PKA signaling at the nuclear level. Along with the lack of allelic loss at the PRKAR1A locus in most of the tumors from this kindred, these data suggested that alteration of PRKAR1A function, not only its complete loss, is sufficient for augmenting PKA activity leading to tumorigenesis in tissues in patients with CNC.

**PPNAD - Primary pigmented nodular adrenocortical disease**

**Primary pigmented nodular adrenocortical disease**

**Disease**
PPNAD is a cause of ACTH-independent Cushing's syndrome. This condition can be difficult to diagnose because hypercortisolism may be periodic and adrenal imaging may not demonstrate an adrenal tumor.

**Hybrid/Mutated gene**
Inactivating PRKAR1A germline mutations are frequent in sporadic and isolated cases of PPNAD.

**Oncogenesis**
Both alleles are frequently inactivated. The wild-type allele can be inactivated by somatic mutations, consistent with the hypothesis of the gene being a tumor suppressor gene.

**Adrenocortical tumors, sporadic**

**Disease**
Patients frequently present with ACTH-independent Cushing's syndrome.

**Hybrid/Mutated gene**
Somatic mutations in the PRKAR1A gene were identified in 3 cases of sporadic adrenocortical tumor. All 3 mutations predicted premature termination of the protein. 17q23-24 loss-of-heterozygosity is a frequent event in adrenal carcinomas.

**Oncogenesis**
Haploinsufficiency of PRKARIA and a reversal of the ratio of R1A to R2B have been proposed to cause tumorigenesis, at least in some cases.

**Myxoma, intracardiac**

**Disease**
Benign neoplasms that occur in 7 per 10,000 individuals. These slowly proliferating lesions arise from subendocardial pluripotent primitive mesenchymal cells, which can differentiate within...
myxomas along a variety of lineages including epithelial, hematopoietic, and muscular.

**Prognosis**
Life span is decreased in patients with myxomas. Morbidity and mortality are the result of embolic stroke, heart failure due to intracardiac obstruction, and rheumatologic symptoms attributed to myxoma-mediated production of IL-6.

**Cytogenetics**
Limited data; 15 cases of myxomas contained clonal numerical and structural abnormalities including telomeric associations.

**Hybrid/Mutated gene**
Mutations of PRKAR1A detected in the coding region of the gene, exons 5, 7 and 8.

**Oncogenesis**
No somatic mutations were detected in cardiac myxomas; haploinsufficiency of PRKAR1A and a reversal of the ratio of RIA to R2B have been proposed may contribute in tumorigenesis.

**Papillary thyroid carcinoma**

**Cytogenetics**
Reciprocal translocation between chromosomes 10 and 17.

**Hybrid/Mutated gene**
RET/PTC2 is formed by the fusion of the RET tyrosine kinase domain with part of the RI-alpha regulatory subunit.

**Abnormal protein**
RET/PTC2.

**Oncogenesis**
The fusion of the RET tyrosine kinase domain with a portion of the RIA gene leads to the expression of RET in the thyroid cells, where it is normally transcriptionally silent.

**References**


This article should be referenced as such: